Format

Send to:

Choose Destination
See comment in PubMed Commons below
Vaccine. 2007 May 10;25(19):3752-62. Epub 2007 Feb 16.

Vaccine adjuvants revisited.

Author information

  • 1Division of Vaccines, Center for Genetic Engineering and Biotechnology, P.O. Box 6162, La Habana 10600, Cuba. julio.aguilar@cigb.edu.cu

Abstract

The development of new adjuvants for human vaccines has become an expanding field of research in the last thirty years, for generating stronger vaccines capable of inducing protective and long-lasting immunity in humans. Instead of such efforts, with several adjuvant strategies approaching to requirements for their clinical application, limitations like adjuvant toxicity remain to be fully surpassed. Here we summarize the current status of adjuvant development, including regulatory recommendations, adjuvant requirements, and adjuvant categories like mineral salts, tensoactive compounds, microorganism-derived adjuvants, emulsions, cytokines, polysaccharides, nucleic acid-based adjuvants, and a section dedicated to particulate antigen delivery systems. The mechanisms of adjuvanticity are also discussed in the light of recent findings on Toll-like receptors' biology and their involvement on immune activation.

PMID:
17336431
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk